ReviewMarine drugs2016
Marine Organisms with Anti-Diabetes Properties.
Review in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 119 citations in OpenAlex.
- Anti-Inflammatory Effects of the Algal Diterpenoid Ruguloptone A by Modulation of M2 Response in Early Diabetic Retinopathy.Pharmaceutics · 2026Article
- Antidiabetic Potential of Sea UrchinCurrent issues in molecular biology · 2025Article
- Marine Fungal Metabolites as Potential Antidiabetic Agents: A Comprehensive Review of Their Structures and Enzyme Inhibitory Activities.Marine drugs · 2025Review
- Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.Cell biochemistry and biophysics · 2025Review
- A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.Current drug metabolism · 2025Review
- Health benefits of fish and fish by-products-a nutritional and functional perspective.Frontiers in nutrition · 2025Review
- Antioxidative, Glucose Management, and Muscle Protein Synthesis Properties of Fish Protein Hydrolysates and Peptides.Journal of agricultural and food chemistry · 2024Review
- Antioxidant and Skin-Whitening Efficacy of a Novel Decapeptide (DP, KGYSSYICDK) Derived from Fish By-Products.Marine drugs · 2024Article
- Isolation and Identification of Lichen Photobionts Collected from Different Environments in North of Portugal and Evaluation of Bioactivities of Their Extracts.Foods (Basel, Switzerland) · 2024Article
- Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives.Marine drugs · 2024Review
- Deep-sea fungal metabolites as potential inhibitors of glucose-regulatory enzymes:Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Algae-Derived Natural Products in Diabetes and Its Complications-Current Advances and Future Prospects.Life (Basel, Switzerland) · 2023Review
- Marine Algal Polyphenols as Skin Protective Agents: Current Status and Future Prospectives.Marine drugs · 2023Review
- Evaluation ofDisease markers · 2023Article
- Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Article
- An Insulin Receptor-Binding Multifunctional Protein fromFoods (Basel, Switzerland) · 2022Article
- Editorial of Special Issue "Microalgal Molecules and Enzymes".International journal of molecular sciences · 2021Article
- Identification, Synthesis, Conformation and Activity of an Insulin-like Peptide from a Sea Anemone.Biomolecules · 2021Article
- Probing the Therapeutic Potential of Marine Phyla by SPE Extraction.Marine drugs · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a chronic degenerative metabolic disease with high morbidity and mortality rates caused by its complications. In recent years, there has been a growing interest in looking for new bioactive compounds to treat this disease, including metabolites of marine origin. Several aquatic organisms have been screened to evaluate their possible anti-diabetes activities, such as bacteria, microalgae, macroalgae, seagrasses, sponges, corals, sea anemones, fish, salmon skin, a shark fusion protein as well as fish and shellfish wastes. Both in vitro and in vivo screenings have been used to test anti-hyperglycemic and anti-diabetic activities of marine organisms. This review summarizes recent discoveries in anti-diabetes properties of several marine organisms as well as marine wastes, existing patents and possible future research directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.